Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005256-97
    Sponsor's Protocol Code Number:SGI-110-06
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-11-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-005256-97
    A.3Full title of the trial
    A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
    SGI-110-06: Studio di fase 3, multicentrico, randomizzato, in aperto con guadecitabina (SGI-110) rispetto al trattamento di prima scelta in adulti con leucemia mieloide acuta trattata in precedenza
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with previously treated acute myeloid leukemia (AML)
    Studio clinico teso a valutare e confrontare la sopravvivenza globale (OS) tra il trattamento con guadecitabina e il trattamento di prima scelta (TC) in adulti con leucemia mieloide acuta (LMA) trattata in precedenza
    A.3.2Name or abbreviated title of the trial where available
    A clinical trial to assess and compare overall survival (OS) between guadecitabine and treatment cho
    Studio clinico teso a valutare e confrontare la sopravvivenza globale (OS) tra il trattamento con gu
    A.4.1Sponsor's protocol code numberSGI-110-06
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorASTEX PHARMACEUTICALS
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstex Pharmaceuticals, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstex Pharmaceuticals, Inc.
    B.5.2Functional name of contact pointClinical trial info. ASTRAL-2
    B.5.3 Address:
    B.5.3.1Street Address4420 Rosewood Drive Ste 200
    B.5.3.2Town/ cityPleasanton
    B.5.3.3Post codeCA94588
    B.5.3.4CountryUnited States
    B.5.4Telephone number00000000
    B.5.5Fax number000000
    B.5.6E-mailASTRAL-2@astx.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGuadecitabine
    D.3.2Product code [SGI-110]
    D.3.4Pharmaceutical form Lyophilisate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 929904-85-8
    D.3.9.2Current sponsor codeSGI-110
    D.3.9.4EV Substance CodeSUB177922
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCytarabine
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    Subcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCITARABINA
    D.3.9.2Current sponsor codeCitarabina
    D.3.9.4EV Substance CodeSUB06880MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCytarabine
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNETOPOSIDE
    D.3.9.1CAS number 33419-42-0
    D.3.9.2Current sponsor codena
    D.3.9.4EV Substance CodeSUB07337MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIdarubicina
    D.3.2Product code [Idarubicina]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIDARUBICINA CLORIDRATO (PER USO INIETTABILE)
    D.3.9.1CAS number 58957-92-9
    D.3.9.2Current sponsor codeIDARUBICINA CLORIDRATO
    D.3.9.4EV Substance CodeSUB08111MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMitoxantrone
    D.3.2Product code [Mitoxantrone]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMITOXANTRONE
    D.3.9.1CAS number 65271-80-9
    D.3.9.2Current sponsor codeMitoxantrone
    D.3.9.4EV Substance CodeSUB09012MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFludarabina
    D.3.2Product code [Fludarabina]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUDARABINA
    D.3.9.1CAS number 21679-14-1
    D.3.9.2Current sponsor codeFLUDARABINA
    D.3.9.4EV Substance CodeSUB07678MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGranulocyte colony-stimulating
    D.3.2Product code [Granulocyte colony-stimulating]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGranulocyte colony-stimulating factor
    D.3.9.1CAS number 143011-72-7
    D.3.9.2Current sponsor codeGranulocyte colony-stimulating factor
    D.3.9.4EV Substance CodeSUB14018MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/l milligram(s)/litre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number600
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDecitabina
    D.3.2Product code [Decitabina]
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDECITABINA
    D.3.9.1CAS number 2353-33-5
    D.3.9.2Current sponsor codeDECITABINA
    D.3.9.4EV Substance CodeSUB06932MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 9
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAzacitidine
    D.3.2Product code [Azacitidine]
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZACITIDINA
    D.3.9.1CAS number 320-67-2
    D.3.9.2Current sponsor codeAZACITIDINA
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Leucemia Mieloide Acuta
    Leucemia Mieloide Acuta
    E.1.1.1Medical condition in easily understood language
    Acute Myeloid Leukemia (AML)
    Acute Myeloid Leukemia (AML)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10024291
    E.1.2Term Leukaemias acute myeloid
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess and compare overall survival (OS) between guadecitabine and
    treatment choice (TC) in adults with previously treated acute myeloid
    leukemia (AML).
    TC options are:
    • High intensity (intermediate or high dose cytarabine [HiDAC];
    mitoxantrone, etoposide, and cytarabine [MEC]; or fludarabine,
    cytarabine, granulocyte colony stimulating factor [G-CSF], +/- idarubicin
    [FLAG/FLAG-Ida])
    • Low intensity (low dose cytarabine [LDAC], decitabine, or azacitidine)
    • Best Supportive Care (BSC).
    BSC will be provided to all subjects as per standard and institutional
    practice.
    • Valutare e confrontare la sopravvivenza globale (OS) tra il trattamento con guadecitabina e il trattamento di prima scelta (TC) in adulti con leucemia mieloide acuta (LMA) trattata in precedenza.
    I trattamenti di prima scelta sono:
    • alta intensità [citarabina a dosaggio intermedio o elevato (HiDAC); mitoxantrone, etoposide e citarabina (MEC); o fludarabina, citarabina, fattore di stimolazione delle colonie di granulociti (G-CSF), ± idarubicina (FLAG/FLAG-Ida)];
    • bassa intensità (citarabina [LDAC], decitabina o azacitidina a basso dosaggio);
    • migliore terapia di supporto (BSC).
    E.2.2Secondary objectives of the trial
    To assess and compare effects of guadecitabine and TC in adults with
    previously treated AML with respect to the following variables:
    Event-free survival (EFS).
    Long-term survival.
    Number of days alive and out of the hospital (NDAOH).
    Transfusion needs.
    Complete response (CR) and CR with partial hematologic recovery (CRh) rates;
    Composite CR rate (CRc). CRc = CR + CR with incomplete blood count
    recovery (CRi) + CR with incomplete platelet recovery (CRp).
    Bridge to hematopoietic cell transplant (HCT).
    Health-related quality of life (QOL).
    Safety.
    Exploratory Objectives
    To assess influence of demographics, disease characteristics, and
    molecular biomarkers on treatment outcomes.
    To evaluate pharmacokinetic (PK) exposure-response relationships with
    XML File Identifier: MnO6IL57BYaEZIbUuMyCIwyUYXQ=
    Page 41/53
    efficacy and safety parameters.
    Valutare e confrontare gli effetti della guadecitabina e del TC in adulti con LMA trattati in precedenza con riferimento alle seguenti variabili:
    • sopravvivenza libera da eventi (EFS);
    • sopravvivenza a lungo termine;
    • numero di giorni in vita e fuori dall'ospedale (NDAOH);
    • esigenze di trasfusione;
    • tassi di risposta completa (CR) e di CR con recupero ematologico parziale (CRh);
    • tasso di CR composita (CRc) [CRc = CR + CR con recupero dell'emocromo incompleto (CRi) + CR con recupero piastrinico incompleto (CRp)];
    • ponte al trapianto di cellule ematopoietiche (HCT);
    • qualità della vita correlata allo stato di salute (QOL);
    • sicurezza.
    Obiettivi esplorativi
    • Valutare l'influenza dei dati demografici, delle caratteristiche della malattia e dei biomarcatori molecolari sui outcome del trattamento.
    • Valutare le relazioni di farmacocinetica (PK) per esposizione-risposta con i parametri di efficacia e sicurezza.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adult subjects =18 years of age who are able to understand study
    procedures, comply with them, and provide written informed consent
    before any study-specific procedure.
    2. History of cytologically or histologically confirmed diagnosis of AML
    (except acute promyelocytic leukemia) according to the 2008 World
    Health Organization (WHO) classification (bone marrow [BM] or
    peripheral blood [PB] blast counts =20%).
    3. Performance status (Eastern Cooperative Oncology Group; ECOG) of 0-
    2.
    4. Subjects with AML previously treated with initial induction therapy
    using a standard intensive chemotherapy regimen, defined as a regiment including cytarabine
    and an anthracycline, and who are refractory to initial induction (primary
    refractory) or in relapse after such initial induction with or without prior HCT.
    5. Subjects must have either PB or BM blasts =5% at time of
    randomization.
    6. Creatinine clearance or glomerular filtration rate =30 mL/min as
    estimated by the Cockroft-Gault (C-G) or other medically acceptable
    formulas, such as MDRD (Modification of Diet in Renal Disease) or CKDEPI
    (the Chronic Kidney Disease Epidemiology Collaboration).
    7. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]; see below* for details) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of childbearing potential must agree to practice 2 highly effective contraceptive
    measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment with guadecitabine, decitabine, or azacitidine and for at
    least 3 months after completing treatment and (b) while receiving treatment with highintensity TC or LDAC and for at least 6 months after completing treatment. Contraceptive measures which may be considered highly effective comprise combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only hormonal contraception(oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is acceptable only if it is consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of birth control.
    * According to recommendations of the CTFG
    (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraceptio n.pdf), a woman is considered of childbearing potential (ie, fertile) following menarche and until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
    Criteri di inclusione
    I soggetti devono soddisfare tutti i criteri di inclusione riportati di seguito.
    1. Soggetti adulti di età pari o superiore a 18 anni in grado di comprendere le procedure dello studio, rispettarle e fornire il consenso informato scritto prima di sottoporsi a qualsiasi procedura specifica dello studio.
    2. Precedente diagnosi di LMA (eccetto leucemia promielocitica acuta) confermata mediante esame citologico o istologico secondo la classificazione del 2008 dell'Organizzazione Mondiale della Sanità (OMS) (conta dei blasti nel midollo osseo [BM] o nel sangue periferico [PB] =20%).
    3. Stato di validità ECOG (Eastern Cooperative Oncology Group) pari a 0-2
    4. Soggetti con LMA precedentemente trattati con terapia di induzione utilizzando un regime di chemioterapia intensiva , definito come un regime, con citarabina e un'antraciclina, e che sono refrattari all'induzione iniziale (refrattari primari) o presentano recidiva dopo tale induzione con o senza pregresso HCT.
    5. Soggetti con blasti PB o BM =5% al momento della randomizzazione.
    6. Clearance della creatinina o velocità di filtrazione glomerulare =30 ml/min secondo la stima con Cockroft-Gault (C-G) o altre formule clinicamente accettabili, quali la MDRD (Modification of Diet in Renal Disease) o la CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).
    7. Le donne in grado di procreare (secondo le raccomandazioni del Clinical Trial Facilitation Group [CTFG]; consultare il protocollo per dettagli al riguardo) non devono essere in gravidanza né allattare al seno e devono presentare un test di gravidanza negativo allo screening. Le donne in grado di procreare e gli uomini con partner di sesso femminile in grado di procreare devono accettare di utilizzare 2 metodi contraccettivi ad alta efficacia ( come descritti nel protocollo) e astenersi dall'iniziare una gravidanza o procreare (a) durante il trattamento con guadecitabina, decitabina o azacitidina e per almeno 3 mesi dopo la conclusione del trattamento e (b) durante il trattamento con TC o LDAC ad alta intensità e per almeno 6 mesi dopo aver completato il trattamento.Le misure contraccettive che possono essere considerate altamente efficaci comprendono la contraccezione ormonale combinata (orale, vaginale o transdermica) o il solo ormone progestinico
    contraccezione (orale, iniettabile, impiantabile) associata ad inibizione dell'ovulazione, dispositivo intrauterino, sistema di rilascio degli ormoni intrauterino, occlusione tubarica bilaterale, astinenza sessuale e vasectomia chirurgicamente efficace. L'astinenza è accettabile solo se è coerente con lo stile di vita preferito e abituale del soggetto. L'astinenza periodica (ad esempio, il calendario, l'ovulazione, i metodi sintotermici o postovulazione) e il ritiro non sono metodi accettabili per il controllo delle nascite.

    * Secondo le raccomandazioni del CTFG
    (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraceptio n.pdf), una donna è considerata potenzialmente fertile (cioè fertile) dopo il menarca e fino a diventare postmenopausale, a meno che non sia permanentemente sterile. I metodi di sterilizzazione permanente includono isterectomia, salpingectomia bilaterale e ovariectomia bilaterale. Un uomo è considerato fertile dopo la pubertà a meno che non sia definitivamente sterile dall'orchettectomia bilaterale.
    E.4Principal exclusion criteria
    1.Know clinically active central nervous (CSN) or extramedullary AML, except leukemia cutis.
    2. Subjects who are in first relapse after initial induction, if they had a response duration of >12 months from date when first response was documented or if they are good candidates for HCT.
    3. BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast
    crisis).
    4. Second malignancy currently requiring active therapy, except breast
    or prostate cancer stable on or responding to endocrine therapy.
    5. Grade 3 or higher Graft Versus Host Disease (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day.(Note: Prednisone at any dose for other indications is allowed.)
    6. Prior treatment with guadecitabine for any indication, or more than 2 cycles decitabine, azacitidine, or guadecitabine.
    7. Hypersensitivity to decitabine, guadecitabine, or any of their
    excipients.
    8. Treated with any investigational therapy within 2 weeks of the first
    dose of study treatment.
    9. Total serum bilirubin >2.5 × upper limit of normal (ULN; except for
    subjects with Gilbert's Syndrome for whom direct bilirubin is <2.5 ×
    ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
    10. Known active human immunodeficiency virus (HIV), hepatitis B virus
    (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier
    status or low viral hepatitis titer on antivirals is allowed.
    11. Known significant mental illness or other condition such as active
    alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with
    the protocol.
    12. Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AMLassociated
    pulmonary disease requiring >2 liters per minute (LPM) oxygen or any other condition that puts the subject at an imminent risk of death.
    13.Subjects with high PB blasts >50% AND poor ECOG PS of 2.
    Saranno esclusi dalla partecipazione allo studio i soggetti che soddisfano uno qualsiasi dei criteri riportati di seguito.
    1. Diagnosi nota di LMA clinicamente attiva a livello del sistema nervoso centrale (SNC) o extramidollare, eccetto la leucemia cutis.
    2. Soggetti non sottoposti in precedenza a HCT e in prima recidiva dopo l'induzione iniziale se hanno presentato una durata della risposta superiore a 12 mesi dalla data in cui è stata documentata la prima risposta OPPURE soggetti che sono candidati idonei per HCT.
    3. Leucemia BCR-ABL-positiva (leucemia mielogena cronica in crisi blastica).
    4. Seconda neoplasia che richiede attualmente una terapia attiva, ad eccezione del tumore al seno o alla prostata trattato stabilmente con terapia endocrina o che risponde a questa terapia.
    5. Malattia del trapianto verso l’ospite (GVHD) di grado 3 o superiore, o GVHD trattata con un inibitore della calcineurina o prednisone a una dose superiore a 5 mg/die. (nota: è consentito il prednisone a qualsiasi dose per altre indicazioni).
    6. Precedente trattamento con guadecitabina, per qualsiasi indicazione o più di 2 cicli di trattamento precedente con decitabina, azacitidina o guadecitabina.
    7. Ipersensibilità alla decitabina, alla guadecitabina o a uno qualsiasi dei loro eccipienti.
    8. Soggetti trattati con una terapia sperimentale nelle 2 settimane che precedono la prima dose del trattamento dello studio.
    9. Bilirubina totale nel siero >2,5 x il limite superiore di normalità (ULN, esclusi i soggetti con sindrome di Gilbert, per i quali la bilirubina diretta è <2,5 ULN) o cirrosi epatica o malattia epatica cronica Child-Pugh Classe B o C.
    10. Infezione attiva nota da virus dell'immunodeficienza umana (HIV), virus dell'epatite B (HBV) o virus dell'epatite C (HCV). È consentito lo stato di portatore inattivo di epatite o epatite virale a basso titolo trattata con antivirali.
    11. Diagnosi nota di malattia mentale significativa o altra condizione quale abuso o dipendenza attiva da alcool o altre sostanze che, a giudizio dello sperimentatore, predispone il soggetto ad alto rischio di inosservanza del protocollo.
    12. Insufficienza cardiaca congestizia refrattaria che non risponde al trattamento medico; infezione attiva resistente a tutti gli antibiotici o malattia polmonare non associata a LMA con una richiesta di ossigeno >2 litri al minuto (LPM) o qualsiasi altra condizione che metta il soggetto a rischio imminente di morte.
    13. Soggetti con blasti >50% e stato di validità ECOG pari a 2
    E.5 End points
    E.5.1Primary end point(s)
    OS, defined as the number of days from date of randomization to date of
    death.
    • Sopravvivenza globale (OS), definita come il numero di giorni dalla data della randomizzazione alla data del decesso.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Treatment cycles to be repeated every 28 days.
    Visits will occur on treatment days, as necessary. Also, during the first 3
    cycles, visits will occur weekly on Days 8, 15, and 22, then on Day 15 in
    Cycles 4-6.
    In Cycles >6, visits will only occur on treatment days (if necessary), with
    study-specified assessments on Day 1.
    Subjects will attend a safety follow-up visit after the last study
    treatment. For subjects who discontinue study treatment before Cycle 6,
    long term follow-up visits will occur monthly until 6 months after the
    start of study treatment, then every 3 months . For subjects who
    discontinue study treatment after Cycle 6, long-term follow-up will be
    every 3 months.
    Survival will be monitored and documented throughout the study.
    I cicli di trattam devono essere ripetuti ogni 28 giorni.Le visite avranno luogo nei giorni di tratt.,secondo necessità.Inoltre, durante i primi 3 cicli, le visite avranno luogo ogni sett. nei giorni 8, 15 e 22; quindi,il giorno 15 nei cicli 4-6. Nel cicli >6 le visite avranno luogo solo nei giorni di tratt. (se necessario),con gli esami specifici dello studio il giorno1.I soggetti si sottoporranno a una visita di safety FU dopo l'ultimo tratt. dello studio. Per i soggetti che interromperanno il tratt. dello studio prima del ciclo 6, sono previste visite di FU mensili a lungo termine fino a 6 mesi dopo l'inizio del tratt. dello studio e in seguito ogni 3 mesi. Per i soggetti che interromperanno il tratt. dello studio dopo il ciclo 6, sono previste visite di FU a lungo termine ogni 3 mesi.
    E.5.2Secondary end point(s)
    EFS defined as the number of days from randomization to the earliest of
    disease progression, treatment discontinuation, start of alternative antileukemia
    therapy (except HCT), or death.
    Survival rate at 1 year after randomization. (Subjects will also be
    followed long term to estimate 2-year survival rate.)
    NDAOH.
    Transfusion independence rate, calculated based on the number of
    subjects without red blood cell (RBC) or platelet transfusion for any
    period of 8 weeks after treatment.
    CR and CRh rates based on modified International Working Group (IWG) 2003 AML
    Response Criteria.
    CRc (CR+CRi+CRp) rate.
    HCT rate. (In subjects who undergo HCT, time to stem cell engraftment
    and 100-day mortality rate post HCT will also be assessed.)
    Duration of combined CR and CRh, defined as the time from first CR or CRh to time of relapse.
    Health-related QOL by EQ-5D (consisting of the EQ-5D-5L descriptive
    system and the EQ Visual Analogue Scale [EQ VAS]).
    Incidence and severity of adverse events (AEs).
    XML File Identifier: MnO6IL57BYaEZIbUuMyCIwyUYXQ=
    Page 43/53
    30- and 60-day all-cause early mortality.
    • Sopravvivenza libera da eventi (EFS), definita come il numero di giorni dalla randomizzazione all'evento che si verifica per primo tra progressione della malattia, interruzione del trattamento, inizio di una terapia antileucemica alternativa (ad eccezione di HCT) o decesso.
    • Tasso di sopravvivenza a 1 anno dopo la randomizzazione (i soggetti saranno, inoltre, seguiti a lungo termine per stimare il tasso di sopravvivenza a 2 anni).
    • NDAOH.
    • Tasso di indipendenza trasfusionale, calcolato in base al numero di soggetti senza trasfusione di globuli rossi (RBC) o piastrine per qualsiasi periodo di 8 settimane dopo il trattamento.
    • CR e CRh tassi si basano sui Criteri di risposta della AML del 2003 International Working Group (IWG) modificati.
    • Tasso CRc (CR+CRi+CRp).
    • Tasso HCT (nei soggetti sottoposti a HCT, sarà valutato anche il tempo fino all'attecchimento delle cellule staminali e il tasso di mortalità a 100 giorni dopo l'HCT).
    • Durata di CR e CRh combinati, definite come il tempo dalla prima CR o CRh al momento della recidiva.
    • QOL correlato allo stato di salute mediante EQ-5D (costituito dal sistema descrittivo EQ-5D-5L e la EQ Visual Analogue Scale [EQ VAS]).
    • Incidenza e gravità degli eventi avversi (AE).
    • Mortalità precoce per tutte le cause a 30 e a 60 giorni.
    E.5.2.1Timepoint(s) of evaluation of this end point
    As for primary endpoint and as specified in protocol.
    Come per gli endpoint primari e come specificato nel protocollo.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Migliore terapia di supporto (BSC); permessa in tutti i braci di studio
    Best Supportive Care only; allowed in all study arms
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA54
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    France
    Germany
    Hungary
    Italy
    Japan
    Korea, Democratic People's Republic of
    Poland
    Spain
    Taiwan
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The primary efficacy endpoint is overall survival (OS), which will be
    assessed after at least 315 death events have occurred.
    The duration of individual subject participation will vary. Subjects may
    continue to receive treatment for as long as they continue to benefit.
    The final study end will be when the last randomized patient has either
    died, withdrawn from the study, or stopped study treatment.
    L'endpoint primario di efficacia è la sopravvivenza globale (OS), che sarà
    valutato dopo si sono verificati almeno 315 eventi di morte.
    La durata della partecipazione soggetto individuale varierà. I soggetti possono
    continuare a ricevere il trattamento per tutto il tempo che continuano a beneficiare.
    La fine studio finale sarà quando l'ultimo paziente randomizzato ha o
    morto, ritirato dallo studio, o interrotto il trattamento in studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 150
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state27
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 155
    F.4.2.2In the whole clinical trial 300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will continue treatment as long as they continue to benefit
    I pazienti continueranno il trattamento fintanto che continuano a beneficiare
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-06-08
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 17:25:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA